BRAF and Langer mesomelic dysplasia: The incidence of LMD has increased over the years [5] and may continue to increase, likely due to the improved overall survival and a prolonged control of extracranial disease with newly approved systemic therapeutic drugs, such as anti-cytotoxic T-lymphocyte antigen (CTLA)-4 antibody and BRAF inhibitors.